Failure to Satisfy Listing Rule (Form 8-K)

As previously reported, on February 18, 2026, Outlook Therapeutics, Inc., a Delaware corporation (the "Company"), received a letter from the Listing Qualifications Staff (the "Nasdaq Staff") of The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that Nasdaq staff had determined to delist the Company's common stock, par value $0.01 per share (the "Common Stock") from the Nasdaq Capital Market because it failed to maintain a minimum bid price of $1.00 per share for 30 consecutive business days, in violation of Nasdaq Listing Rule 5550(a)(2).

On June 26, 2026, the Company received a letter from the Nasdaq Staff notifying the Company that, because the closing bid price of the Company's common stock had been at $1.00 per share or greater for the ten consecutive business days between June 11, 2026 - June 25, 2026, the Company had regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market and that this matter is now closed.